PVs in CHEK2 was associated with increased risk of SLL (OR = 3.65, 95% CI: 1.54–7.24), DLBCL (OR = 1.93, 95% CI: 1.23–2.89), and MM (OR = 1.75, 95% CI: 1.24–2.41). This evidence concerns the gene CHEK2 and diffuse large B-cell lymphoma.